The proposed bill would amend current statutes by appropriating $10 million from the state General Fund for fiscal year 2026 to the Department of Health Services (DHS) specifically for grants related to clinical trials or research on midomafetamine as a treatment for Post Traumatic Stress Disorder (PTSD). This funding is aimed at supporting entities that have completed at least one late-stage clinical trial and are actively participating in the FDA drug review process for midomafetamine.

Additionally, the bill includes a provision that exempts this appropriation from lapsing, meaning the allocated funds would not expire at the end of the fiscal year, allowing for continued use in the specified research. The bill's language would be inserted into the existing statutes, enhancing the legal framework surrounding funding for mental health research and treatment options.